CO6761320A2 - Derivados de piperidina puenteada - Google Patents
Derivados de piperidina puenteadaInfo
- Publication number
- CO6761320A2 CO6761320A2 CO13176486A CO13176486A CO6761320A2 CO 6761320 A2 CO6761320 A2 CO 6761320A2 CO 13176486 A CO13176486 A CO 13176486A CO 13176486 A CO13176486 A CO 13176486A CO 6761320 A2 CO6761320 A2 CO 6761320A2
- Authority
- CO
- Colombia
- Prior art keywords
- lower alkyl
- halogen
- ring
- substituted
- amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula:en la que:hetarilo I es un grupo heteroarilo de cinco o seis eslabones, que contiene de 1 a 3 heteroátomos elegidos entre S y N;hetarilo II es un grupo heteroarilo de seis eslabones, que contiene de 1 a 3 heteroátomos elegidos entre S y N, o es un sistema cíclico de dos miembros que contiene de 1 a 4 heteroátomos elegidos entre S y N, de los que por lo menos un anillo es de naturaleza aromática;Res alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno o halógeno;Res alquilo inferior, alquilo inferior sustituido por halógeno, halógeno, alcoxi inferior, cicloalquilo sustituido por alquilo inferior o alquilo inferior sustituido por halógeno,o es alquilo inferior sustituido por hidroxi, o es furilo, o es O-bencilo,(CH)-fenilo, opcionalmente sustituido por halógeno, alcoxi inferior, alquilo inferior sustituido por halógeno, alquilo inferior o por ciano;Res hidrógeno o alquilo inferior;Y es (CH)-, -CHOCH-, -CHO-, CHS-, -CHSCH- y está unido a dos de los átomos de carbono del anillo, la unión se realiza con los átomos de carbono a y b del anillo o con los átomos de carbono c y d del anillo;p es el número 0 ó 1;m es el número 0, 1 ó 2; si m es 2, entonces Rpuede ser igual o diferente;n es el número 2 ó 3;o es el número 0, 1 ó 2, si o es 2, entonces Rpuede ser igual o diferente; o a sus sales de adición de ácido farmacéuticamente activas.Los compuestos presentes de la fórmula I son moduladores de betaamiloide y por ello pueden ser útiles para el tratamiento o prevención de una enfermedad asociada con la deposición de ß-amiloide en el cerebro, en particular la enfermedad de Alzheimer y otras enfermedades, como son la angiopatía cerebral amiloide, la hemorragia cerebral hereditaria con amiloidosis de tipo Dutch (HCHWA-D), la demencia multiinfarto, la demencia pugilística y el síndrome de Down.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11156587 | 2011-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6761320A2 true CO6761320A2 (es) | 2013-09-30 |
Family
ID=45757448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13176486A CO6761320A2 (es) | 2011-03-02 | 2013-07-25 | Derivados de piperidina puenteada |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8703763B2 (es) |
| EP (1) | EP2681214B1 (es) |
| JP (1) | JP5753591B2 (es) |
| KR (1) | KR101550122B1 (es) |
| CN (1) | CN103403003B (es) |
| BR (1) | BR112013021924A2 (es) |
| CA (1) | CA2824239A1 (es) |
| CL (1) | CL2013002474A1 (es) |
| CO (1) | CO6761320A2 (es) |
| CR (1) | CR20130358A (es) |
| EA (1) | EA025035B1 (es) |
| EC (1) | ECSP13012858A (es) |
| IL (1) | IL227251A (es) |
| MA (1) | MA34964B1 (es) |
| MX (1) | MX2013009031A (es) |
| MY (1) | MY167264A (es) |
| PE (1) | PE20140250A1 (es) |
| SG (1) | SG193239A1 (es) |
| UA (1) | UA110368C2 (es) |
| WO (1) | WO2012116965A1 (es) |
| ZA (1) | ZA201305322B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5321839B2 (ja) * | 2007-04-25 | 2013-10-23 | 日産化学工業株式会社 | ポリイミド前駆体及びポリイミド並びに画像形成下層膜塗布液 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| EP3347363B1 (en) * | 2015-09-09 | 2020-01-01 | H. Hoffnabb-La Roche Ag | N-(3-azabicyclo[3.2.1]octan-8-yl)-8-(4-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[l,5-a]pyridin-2-amine derivatives as gamma-secretase modulators for treating alzheimer's disease |
| MX2018005890A (es) | 2015-11-12 | 2018-08-15 | Hoffmann La Roche | Composiciones para tratar atrofia muscular espinal. |
| CN108137579B (zh) * | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
| EP3475279B1 (en) * | 2016-06-27 | 2021-07-14 | F. Hoffmann-La Roche AG | Triazolopyridines as gamma-secretase modulators |
| EP3484884B1 (en) | 2016-07-14 | 2021-01-27 | Hoffmann-La Roche AG | Fused pyrimidine derivatives |
| JP6912574B2 (ja) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| CN109476670B (zh) * | 2016-10-04 | 2022-06-28 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
| JP7111704B2 (ja) * | 2016-11-01 | 2022-08-02 | エフ．ホフマン－ラ ロシュ アーゲー | 二環式ヘテロアリール誘導体 |
| WO2018087018A1 (en) | 2016-11-08 | 2018-05-17 | F. Hoffmann-La Roche Ag | Phenoxytriazoles |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| EA201992878A1 (ru) | 2017-06-05 | 2020-05-08 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни хантингтона |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
| WO2019121596A1 (en) * | 2017-12-19 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Triazolo pyridines as modulators of gamma-secretase |
| EP3743428B1 (en) | 2018-01-22 | 2022-01-19 | F. Hoffmann-La Roche AG | Triazolo-azepine derivatives |
| CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
| PT3846903T (pt) * | 2018-09-03 | 2023-12-14 | Hoffmann La Roche | Derivados heteroarílicos bicíclicos |
| US20220056036A1 (en) * | 2018-12-13 | 2022-02-24 | Hoffmann-La Roche Inc. | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease |
| CN113372364A (zh) * | 2020-03-10 | 2021-09-10 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| EA014057B1 (ru) * | 2005-10-06 | 2010-08-30 | Ниппон Сода Ко., Лтд. | Поперечно связанные соединения циклических аминов и средства для борьбы с вредителями |
| CA2713716A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
-
2012
- 2012-02-27 US US13/405,404 patent/US8703763B2/en not_active Expired - Fee Related
- 2012-02-28 JP JP2013555846A patent/JP5753591B2/ja not_active Expired - Fee Related
- 2012-02-28 EP EP12705884.0A patent/EP2681214B1/en not_active Not-in-force
- 2012-02-28 MA MA36238A patent/MA34964B1/fr unknown
- 2012-02-28 CN CN201280011284.3A patent/CN103403003B/zh not_active Expired - Fee Related
- 2012-02-28 MY MYPI2013003198A patent/MY167264A/en unknown
- 2012-02-28 MX MX2013009031A patent/MX2013009031A/es active IP Right Grant
- 2012-02-28 SG SG2013065107A patent/SG193239A1/en unknown
- 2012-02-28 WO PCT/EP2012/053301 patent/WO2012116965A1/en active Application Filing
- 2012-02-28 PE PE2013002000A patent/PE20140250A1/es not_active Application Discontinuation
- 2012-02-28 KR KR1020137025946A patent/KR101550122B1/ko not_active IP Right Cessation
- 2012-02-28 UA UAA201311595A patent/UA110368C2/uk unknown
- 2012-02-28 CA CA2824239A patent/CA2824239A1/en not_active Abandoned
- 2012-02-28 EA EA201391209A patent/EA025035B1/ru not_active IP Right Cessation
- 2012-02-28 BR BR112013021924-6A patent/BR112013021924A2/pt not_active IP Right Cessation
-
2013
- 2013-06-27 IL IL227251A patent/IL227251A/en active IP Right Grant
- 2013-07-15 ZA ZA2013/05322A patent/ZA201305322B/en unknown
- 2013-07-23 CR CR20130358A patent/CR20130358A/es unknown
- 2013-07-25 CO CO13176486A patent/CO6761320A2/es unknown
- 2013-08-28 CL CL2013002474A patent/CL2013002474A1/es unknown
- 2013-08-30 EC ECSP13012858 patent/ECSP13012858A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL227251A (en) | 2016-09-29 |
| US8703763B2 (en) | 2014-04-22 |
| UA110368C2 (en) | 2015-12-25 |
| SG193239A1 (en) | 2013-10-30 |
| JP5753591B2 (ja) | 2015-07-22 |
| US20120225884A1 (en) | 2012-09-06 |
| CN103403003A (zh) | 2013-11-20 |
| EP2681214A1 (en) | 2014-01-08 |
| AU2012222426A1 (en) | 2013-07-11 |
| MY167264A (en) | 2018-08-14 |
| PE20140250A1 (es) | 2014-03-12 |
| BR112013021924A2 (pt) | 2020-10-20 |
| KR101550122B1 (ko) | 2015-09-03 |
| CN103403003B (zh) | 2016-09-14 |
| ECSP13012858A (es) | 2013-10-31 |
| KR20130140142A (ko) | 2013-12-23 |
| CR20130358A (es) | 2013-10-03 |
| EA201391209A1 (ru) | 2013-12-30 |
| CL2013002474A1 (es) | 2014-05-30 |
| EP2681214B1 (en) | 2017-03-22 |
| IL227251A0 (en) | 2013-09-30 |
| MA34964B1 (fr) | 2014-03-01 |
| CA2824239A1 (en) | 2012-09-07 |
| MX2013009031A (es) | 2013-09-02 |
| NZ612525A (en) | 2015-08-28 |
| ZA201305322B (en) | 2014-04-30 |
| EA025035B1 (ru) | 2016-11-30 |
| WO2012116965A1 (en) | 2012-09-07 |
| JP2014506903A (ja) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6761320A2 (es) | Derivados de piperidina puenteada | |
| AR080177A1 (es) | Derivados de piperidina, un procedimiento para su preparacion, y su uso en medicamentos para el tratamiento de enfermedades mentales asociadas a la deposicion del beta-amiloide en el cerebro. | |
| AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| CL2018000036A1 (es) | Derivados etinilo | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR070130A1 (es) | Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento | |
| AR107010A1 (es) | Derivados de piperidina puenteados | |
| AR092628A1 (es) | Piridinonas biciclicas | |
| AR066509A1 (es) | Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide. | |
| AR105965A1 (es) | Derivados de piperidina puenteados | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR080083A1 (es) | Moduladores de gamma-secretasa | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
| NI201300072A (es) | Derivados de heteroarilo como moduladores nachr alfa 7 | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR110001A1 (es) | Derivados heteroarilo bicíclicos | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| AR110122A1 (es) | Fenoxitriazoles | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR109829A1 (es) | Derivados de piperidina puenteados |